

WHAT IS CLAIMED IS:

Sub
A-7
1. A vaccine comprising a polypeptide, including immunogenic fragments thereof, having an amino acid
5 sequence at least 65% identical to the amino acid sequence of SEQ ID NO:6.

2. The vaccine of claim 1 wherein said amino acid
10 sequence is at least 80% identical to the amino acid sequence of SEQ ID NO:6.

3. The vaccine of claim 1 wherein said amino acid
sequence is at least 95% identical to the amino acid
sequence of SEQ ID NO:6.

15
4. The vaccine of claim 1 wherein said amino acid
sequence is identical to the amino acid sequence of SEQ ID
NO:6.

20 5. A vaccine comprising a polypeptide, including immunogenic fragments thereof, having an amino acid sequence at least 65% identical to the amino acid sequence of SEQ ID NO:8.

25 6. The vaccine of claim 5 wherein said amino acid sequence is at least 80% identical to the amino acid sequence of SEQ ID NO:8.

30 7. The vaccine of claim 5 wherein said amino acid sequence is at least 95% identical to the amino acid sequence of SEQ ID NO:8.

8. The vaccine of claim 5 wherein said amino acid sequence is identical to the amino acid sequence of SEQ ID NO:8.

5 9. An antiserum produced by immunizing an animal with a polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8.

10 10. An isolated antibody that binds specifically to a polypeptide selected from the group consisting of the polypeptides according to claims 1, 2, 3, 4, 5, 6, 7, and 8.

15 11. The antibody of claim 10 wherein the antibody is a monoclonal antibody.

12. An engineered cell producing a monoclonal antibody of claim 11.

20 13. An antiserum produced by immunizing an animal with the polypeptide of SEQ ID NO: 6.

14. An antiserum produced by immunizing an animal with the polypeptide of SEQ ID NO: 8.

25 15. An isolated recombinant antibody that binds specifically to a polypeptide selected from the group consisting of the polypeptides of claims 1,2,3,4,5,6,7, and 8.

30 16. A vaccine comprising :
a. one or more *S. pneumoniae* polypeptides selected

from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8; and

b. a pharmaceutically acceptable diluent , carrier or excipient;

5 wherein said polypeptide is present in an amount effective to elicit protective antibodies in an animal against an organism of the genus *Streptococcus*.

10 17. A method of preventing or attenuating an infection caused by a member of the genus *Streptococcus* in an animal, comprising administering to said animal a polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8, and wherein said polypeptide is administered in an amount
15 effective to prevent or attenuate said infection.

18. A method of preventing pneumococcal infection by administering to an animal the vaccine according to claim
20 16.

25 19. A method of preventing or attenuating an infection caused by a member of the genus *Streptococcus* in an animal, comprising administering to said animal an antibody according to claim 10, wherein said antibody is administered in an amount effective to prevent or
30 attenuate said infection.

20. A vaccine comprising a microbial organism transformed with polynucleotides, and thereby expressing
30 the polypeptides, or fragments thereof, selected from the group consisting of Sp128 and Sp130.

21. A method of preventing or attenuating an infection caused by a member of the genus *Streptococcus* in an animal, comprising administering to said animal a vaccine according to claim 20, wherein said antibody is administered in an amount effective to prevent or attenuate said infection.

22. The vaccine according to claim 20, wherein said transformed microorganism is selected from the group consisting of *Salmonella*, *Mycobacteria*, *Streptococcus*, poxviruses, and adenoviruses.

ADD
A8

15

20

25

30